NCT01636102View on ClinicalTrials.gov

Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Human Influenza
Interventions
BIOLOGICAL

Trivalent influenza virus vaccine (TIV)

A single 0.5 mL dose of the study vaccine supplied in prefilled syringes and administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm

Trial Locations (1)

BC001

University Hospital Ghent, Center for Vaccinology, Prof.Dr. G Leroux Roels, Ghent

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY